nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—ABCG2—Teniposide—lymphatic system cancer	0.131	0.214	CbGbCtD
Pazopanib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0917	0.15	CbGbCtD
Pazopanib—CYP1A2—Carmustine—lymphatic system cancer	0.0804	0.131	CbGbCtD
Pazopanib—ABCG2—Vincristine—lymphatic system cancer	0.0631	0.103	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—lymphatic system cancer	0.0481	0.0785	CbGbCtD
Pazopanib—ABCG2—Methotrexate—lymphatic system cancer	0.0382	0.0623	CbGbCtD
Pazopanib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0331	0.054	CbGbCtD
Pazopanib—CYP3A4—Cytarabine—lymphatic system cancer	0.0287	0.0469	CbGbCtD
Pazopanib—CYP3A4—Teniposide—lymphatic system cancer	0.0283	0.0462	CbGbCtD
Pazopanib—ABCB1—Vincristine—lymphatic system cancer	0.0227	0.0371	CbGbCtD
Pazopanib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0198	0.0323	CbGbCtD
Pazopanib—ABCB1—Methotrexate—lymphatic system cancer	0.0138	0.0225	CbGbCtD
Pazopanib—CYP3A4—Vincristine—lymphatic system cancer	0.0136	0.0222	CbGbCtD
Pazopanib—PLK4—Etoposide—Teniposide—lymphatic system cancer	0.00804	1	CbGdCrCtD
Pazopanib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000728	0.00192	CcSEcCtD
Pazopanib—Weight decreased—Vincristine—lymphatic system cancer	0.000728	0.00192	CcSEcCtD
Pazopanib—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000724	0.00191	CcSEcCtD
Pazopanib—Flushing—Bleomycin—lymphatic system cancer	0.000718	0.00189	CcSEcCtD
Pazopanib—Anorexia—Fludarabine—lymphatic system cancer	0.000714	0.00188	CcSEcCtD
Pazopanib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000709	0.00187	CcSEcCtD
Pazopanib—Proteinuria—Methotrexate—lymphatic system cancer	0.000709	0.00187	CcSEcCtD
Pazopanib—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000708	0.00186	CcSEcCtD
Pazopanib—Myocardial infarction—Vincristine—lymphatic system cancer	0.000704	0.00185	CcSEcCtD
Pazopanib—Stomatitis—Vincristine—lymphatic system cancer	0.0007	0.00184	CcSEcCtD
Pazopanib—Protein urine present—Methotrexate—lymphatic system cancer	0.000699	0.00184	CcSEcCtD
Pazopanib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000697	0.00184	CcSEcCtD
Pazopanib—Chills—Bleomycin—lymphatic system cancer	0.000694	0.00183	CcSEcCtD
Pazopanib—Skin discolouration—Methotrexate—lymphatic system cancer	0.000689	0.00182	CcSEcCtD
Pazopanib—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000689	0.00182	CcSEcCtD
Pazopanib—Nausea—Mechlorethamine—lymphatic system cancer	0.000687	0.00181	CcSEcCtD
Pazopanib—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000685	0.00181	CcSEcCtD
Pazopanib—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000685	0.0018	CcSEcCtD
Pazopanib—Alopecia—Bleomycin—lymphatic system cancer	0.000683	0.0018	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000683	0.0018	CcSEcCtD
Pazopanib—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000681	0.0018	CcSEcCtD
Pazopanib—Jaundice—Mitoxantrone—lymphatic system cancer	0.000681	0.0018	CcSEcCtD
Pazopanib—Haemoglobin—Carmustine—lymphatic system cancer	0.000678	0.00179	CcSEcCtD
Pazopanib—Haemorrhage—Carmustine—lymphatic system cancer	0.000675	0.00178	CcSEcCtD
Pazopanib—Abdominal pain—Teniposide—lymphatic system cancer	0.000674	0.00178	CcSEcCtD
Pazopanib—Erythema—Bleomycin—lymphatic system cancer	0.000673	0.00177	CcSEcCtD
Pazopanib—Paraesthesia—Fludarabine—lymphatic system cancer	0.000673	0.00177	CcSEcCtD
Pazopanib—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000672	0.00177	CcSEcCtD
Pazopanib—Dyspnoea—Fludarabine—lymphatic system cancer	0.000668	0.00176	CcSEcCtD
Pazopanib—Haematuria—Mitoxantrone—lymphatic system cancer	0.000666	0.00176	CcSEcCtD
Pazopanib—Oedema peripheral—Carmustine—lymphatic system cancer	0.000665	0.00175	CcSEcCtD
Pazopanib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000663	0.00175	CcSEcCtD
Pazopanib—Dyspepsia—Fludarabine—lymphatic system cancer	0.00066	0.00174	CcSEcCtD
Pazopanib—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.000658	0.00173	CcSEcCtD
Pazopanib—Decreased appetite—Fludarabine—lymphatic system cancer	0.000651	0.00172	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000647	0.00171	CcSEcCtD
Pazopanib—Fatigue—Fludarabine—lymphatic system cancer	0.000646	0.0017	CcSEcCtD
Pazopanib—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000641	0.00169	CcSEcCtD
Pazopanib—Pain—Fludarabine—lymphatic system cancer	0.000641	0.00169	CcSEcCtD
Pazopanib—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000639	0.00168	CcSEcCtD
Pazopanib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000636	0.00168	CcSEcCtD
Pazopanib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000633	0.00167	CcSEcCtD
Pazopanib—Urethral disorder—Vincristine—lymphatic system cancer	0.000632	0.00166	CcSEcCtD
Pazopanib—Eye disorder—Carmustine—lymphatic system cancer	0.000631	0.00166	CcSEcCtD
Pazopanib—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000631	0.00166	CcSEcCtD
Pazopanib—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000628	0.00165	CcSEcCtD
Pazopanib—Flushing—Carmustine—lymphatic system cancer	0.000626	0.00165	CcSEcCtD
Pazopanib—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000623	0.00164	CcSEcCtD
Pazopanib—Anaemia—Bleomycin—lymphatic system cancer	0.000622	0.00164	CcSEcCtD
Pazopanib—Asthenia—Teniposide—lymphatic system cancer	0.000612	0.00161	CcSEcCtD
Pazopanib—Melaena—Methotrexate—lymphatic system cancer	0.000608	0.0016	CcSEcCtD
Pazopanib—Pruritus—Teniposide—lymphatic system cancer	0.000603	0.00159	CcSEcCtD
Pazopanib—Leukopenia—Bleomycin—lymphatic system cancer	0.000603	0.00159	CcSEcCtD
Pazopanib—Cardiac disorder—Vincristine—lymphatic system cancer	0.000598	0.00158	CcSEcCtD
Pazopanib—Alopecia—Carmustine—lymphatic system cancer	0.000596	0.00157	CcSEcCtD
Pazopanib—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000594	0.00157	CcSEcCtD
Pazopanib—Mental disorder—Carmustine—lymphatic system cancer	0.000591	0.00156	CcSEcCtD
Pazopanib—Erythema—Carmustine—lymphatic system cancer	0.000588	0.00155	CcSEcCtD
Pazopanib—Malnutrition—Carmustine—lymphatic system cancer	0.000588	0.00155	CcSEcCtD
Pazopanib—Cough—Bleomycin—lymphatic system cancer	0.000587	0.00155	CcSEcCtD
Pazopanib—Angiopathy—Vincristine—lymphatic system cancer	0.000585	0.00154	CcSEcCtD
Pazopanib—Diarrhoea—Teniposide—lymphatic system cancer	0.000583	0.00154	CcSEcCtD
Pazopanib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000581	0.00153	CcSEcCtD
Pazopanib—Chest pain—Bleomycin—lymphatic system cancer	0.000573	0.00151	CcSEcCtD
Pazopanib—Myalgia—Bleomycin—lymphatic system cancer	0.000573	0.00151	CcSEcCtD
Pazopanib—Alopecia—Vincristine—lymphatic system cancer	0.000569	0.0015	CcSEcCtD
Pazopanib—Mental disorder—Vincristine—lymphatic system cancer	0.000564	0.00149	CcSEcCtD
Pazopanib—Chills—Mitoxantrone—lymphatic system cancer	0.000563	0.00148	CcSEcCtD
Pazopanib—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000563	0.00148	CcSEcCtD
Pazopanib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000555	0.00146	CcSEcCtD
Pazopanib—Vision blurred—Carmustine—lymphatic system cancer	0.000554	0.00146	CcSEcCtD
Pazopanib—Oedema—Bleomycin—lymphatic system cancer	0.000549	0.00145	CcSEcCtD
Pazopanib—Erythema—Mitoxantrone—lymphatic system cancer	0.000546	0.00144	CcSEcCtD
Pazopanib—Infection—Bleomycin—lymphatic system cancer	0.000546	0.00144	CcSEcCtD
Pazopanib—Anaemia—Carmustine—lymphatic system cancer	0.000543	0.00143	CcSEcCtD
Pazopanib—Vomiting—Teniposide—lymphatic system cancer	0.000542	0.00143	CcSEcCtD
Pazopanib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000538	0.00142	CcSEcCtD
Pazopanib—Asthenia—Fludarabine—lymphatic system cancer	0.000538	0.00142	CcSEcCtD
Pazopanib—Rash—Teniposide—lymphatic system cancer	0.000538	0.00142	CcSEcCtD
Pazopanib—Dermatitis—Teniposide—lymphatic system cancer	0.000537	0.00142	CcSEcCtD
Pazopanib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000535	0.00141	CcSEcCtD
Pazopanib—Headache—Teniposide—lymphatic system cancer	0.000534	0.00141	CcSEcCtD
Pazopanib—Pruritus—Fludarabine—lymphatic system cancer	0.00053	0.0014	CcSEcCtD
Pazopanib—Leukopenia—Carmustine—lymphatic system cancer	0.000526	0.00139	CcSEcCtD
Pazopanib—Anorexia—Bleomycin—lymphatic system cancer	0.000524	0.00138	CcSEcCtD
Pazopanib—Anaemia—Vincristine—lymphatic system cancer	0.000518	0.00137	CcSEcCtD
Pazopanib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000515	0.00136	CcSEcCtD
Pazopanib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000513	0.00135	CcSEcCtD
Pazopanib—Hypertension—Carmustine—lymphatic system cancer	0.000507	0.00134	CcSEcCtD
Pazopanib—Nausea—Teniposide—lymphatic system cancer	0.000506	0.00133	CcSEcCtD
Pazopanib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000505	0.00133	CcSEcCtD
Pazopanib—Hepatic failure—Methotrexate—lymphatic system cancer	0.000503	0.00133	CcSEcCtD
Pazopanib—Leukopenia—Vincristine—lymphatic system cancer	0.000502	0.00132	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000501	0.00132	CcSEcCtD
Pazopanib—Myalgia—Carmustine—lymphatic system cancer	0.0005	0.00132	CcSEcCtD
Pazopanib—Chest pain—Carmustine—lymphatic system cancer	0.0005	0.00132	CcSEcCtD
Pazopanib—Paraesthesia—Bleomycin—lymphatic system cancer	0.000493	0.0013	CcSEcCtD
Pazopanib—Dyspnoea—Bleomycin—lymphatic system cancer	0.00049	0.00129	CcSEcCtD
Pazopanib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000489	0.00129	CcSEcCtD
Pazopanib—Hypertension—Vincristine—lymphatic system cancer	0.000484	0.00128	CcSEcCtD
Pazopanib—Oedema—Carmustine—lymphatic system cancer	0.00048	0.00126	CcSEcCtD
Pazopanib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000478	0.00126	CcSEcCtD
Pazopanib—Myalgia—Vincristine—lymphatic system cancer	0.000478	0.00126	CcSEcCtD
Pazopanib—Cough—Mitoxantrone—lymphatic system cancer	0.000477	0.00126	CcSEcCtD
Pazopanib—Infection—Carmustine—lymphatic system cancer	0.000476	0.00126	CcSEcCtD
Pazopanib—Vomiting—Fludarabine—lymphatic system cancer	0.000476	0.00126	CcSEcCtD
Pazopanib—Rash—Fludarabine—lymphatic system cancer	0.000472	0.00125	CcSEcCtD
Pazopanib—Dermatitis—Fludarabine—lymphatic system cancer	0.000472	0.00124	CcSEcCtD
Pazopanib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000472	0.00124	CcSEcCtD
Pazopanib—Pain—Bleomycin—lymphatic system cancer	0.00047	0.00124	CcSEcCtD
Pazopanib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00047	0.00124	CcSEcCtD
Pazopanib—Headache—Fludarabine—lymphatic system cancer	0.000469	0.00124	CcSEcCtD
Pazopanib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000465	0.00123	CcSEcCtD
Pazopanib—Chest pain—Mitoxantrone—lymphatic system cancer	0.000465	0.00123	CcSEcCtD
Pazopanib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000465	0.00123	CcSEcCtD
Pazopanib—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000461	0.00122	CcSEcCtD
Pazopanib—Lethargy—Methotrexate—lymphatic system cancer	0.000461	0.00122	CcSEcCtD
Pazopanib—Oedema—Vincristine—lymphatic system cancer	0.000458	0.00121	CcSEcCtD
Pazopanib—Anorexia—Carmustine—lymphatic system cancer	0.000457	0.0012	CcSEcCtD
Pazopanib—Infection—Vincristine—lymphatic system cancer	0.000455	0.0012	CcSEcCtD
Pazopanib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000449	0.00118	CcSEcCtD
Pazopanib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000448	0.00118	CcSEcCtD
Pazopanib—Oedema—Mitoxantrone—lymphatic system cancer	0.000446	0.00118	CcSEcCtD
Pazopanib—Nausea—Fludarabine—lymphatic system cancer	0.000445	0.00117	CcSEcCtD
Pazopanib—Infection—Mitoxantrone—lymphatic system cancer	0.000443	0.00117	CcSEcCtD
Pazopanib—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000443	0.00117	CcSEcCtD
Pazopanib—Shock—Mitoxantrone—lymphatic system cancer	0.000439	0.00116	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000437	0.00115	CcSEcCtD
Pazopanib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000436	0.00115	CcSEcCtD
Pazopanib—Anorexia—Vincristine—lymphatic system cancer	0.000436	0.00115	CcSEcCtD
Pazopanib—Insomnia—Carmustine—lymphatic system cancer	0.000434	0.00114	CcSEcCtD
Pazopanib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000433	0.00114	CcSEcCtD
Pazopanib—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000431	0.00114	CcSEcCtD
Pazopanib—Paraesthesia—Carmustine—lymphatic system cancer	0.000431	0.00113	CcSEcCtD
Pazopanib—Dyspnoea—Carmustine—lymphatic system cancer	0.000428	0.00113	CcSEcCtD
Pazopanib—Somnolence—Carmustine—lymphatic system cancer	0.000426	0.00112	CcSEcCtD
Pazopanib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000425	0.00112	CcSEcCtD
Pazopanib—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000417	0.0011	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000417	0.0011	CcSEcCtD
Pazopanib—Decreased appetite—Carmustine—lymphatic system cancer	0.000417	0.0011	CcSEcCtD
Pazopanib—Insomnia—Vincristine—lymphatic system cancer	0.000414	0.00109	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000414	0.00109	CcSEcCtD
Pazopanib—Paraesthesia—Vincristine—lymphatic system cancer	0.000411	0.00108	CcSEcCtD
Pazopanib—Pain—Carmustine—lymphatic system cancer	0.00041	0.00108	CcSEcCtD
Pazopanib—Breast disorder—Methotrexate—lymphatic system cancer	0.000408	0.00108	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000406	0.00107	CcSEcCtD
Pazopanib—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0004	0.00106	CcSEcCtD
Pazopanib—Decreased appetite—Vincristine—lymphatic system cancer	0.000398	0.00105	CcSEcCtD
Pazopanib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000397	0.00105	CcSEcCtD
Pazopanib—Somnolence—Mitoxantrone—lymphatic system cancer	0.000396	0.00104	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000395	0.00104	CcSEcCtD
Pazopanib—Fatigue—Vincristine—lymphatic system cancer	0.000395	0.00104	CcSEcCtD
Pazopanib—Asthenia—Bleomycin—lymphatic system cancer	0.000394	0.00104	CcSEcCtD
Pazopanib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000392	0.00103	CcSEcCtD
Pazopanib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000392	0.00103	CcSEcCtD
Pazopanib—Pain—Vincristine—lymphatic system cancer	0.000391	0.00103	CcSEcCtD
Pazopanib—Pruritus—Bleomycin—lymphatic system cancer	0.000389	0.00102	CcSEcCtD
Pazopanib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000388	0.00102	CcSEcCtD
Pazopanib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000384	0.00101	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000383	0.00101	CcSEcCtD
Pazopanib—Pain—Mitoxantrone—lymphatic system cancer	0.000381	0.001	CcSEcCtD
Pazopanib—Abdominal pain—Carmustine—lymphatic system cancer	0.000379	0.000999	CcSEcCtD
Pazopanib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000374	0.000987	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—lymphatic system cancer	0.000365	0.000963	CcSEcCtD
Pazopanib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000365	0.000961	CcSEcCtD
Pazopanib—Abdominal pain—Vincristine—lymphatic system cancer	0.000362	0.000954	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000357	0.00094	CcSEcCtD
Pazopanib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000352	0.000929	CcSEcCtD
Pazopanib—Vomiting—Bleomycin—lymphatic system cancer	0.000349	0.000921	CcSEcCtD
Pazopanib—Infestation—Methotrexate—lymphatic system cancer	0.000348	0.000918	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000348	0.000918	CcSEcCtD
Pazopanib—Rash—Bleomycin—lymphatic system cancer	0.000346	0.000913	CcSEcCtD
Pazopanib—Dermatitis—Bleomycin—lymphatic system cancer	0.000346	0.000912	CcSEcCtD
Pazopanib—Asthenia—Carmustine—lymphatic system cancer	0.000344	0.000907	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—lymphatic system cancer	0.000339	0.000895	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—lymphatic system cancer	0.000332	0.000875	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000329	0.000868	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—lymphatic system cancer	0.000328	0.000866	CcSEcCtD
Pazopanib—Asthenia—Vincristine—lymphatic system cancer	0.000328	0.000866	CcSEcCtD
Pazopanib—Diarrhoea—Carmustine—lymphatic system cancer	0.000328	0.000865	CcSEcCtD
Pazopanib—Nausea—Bleomycin—lymphatic system cancer	0.000326	0.00086	CcSEcCtD
Pazopanib—Asthenia—Mitoxantrone—lymphatic system cancer	0.00032	0.000843	CcSEcCtD
Pazopanib—Dizziness—Carmustine—lymphatic system cancer	0.000317	0.000836	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000314	0.000828	CcSEcCtD
Pazopanib—Diarrhoea—Vincristine—lymphatic system cancer	0.000313	0.000826	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000313	0.000824	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000309	0.000814	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000306	0.000808	CcSEcCtD
Pazopanib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000305	0.000804	CcSEcCtD
Pazopanib—Vomiting—Carmustine—lymphatic system cancer	0.000305	0.000804	CcSEcCtD
Pazopanib—Dizziness—Vincristine—lymphatic system cancer	0.000303	0.000798	CcSEcCtD
Pazopanib—Rash—Carmustine—lymphatic system cancer	0.000302	0.000797	CcSEcCtD
Pazopanib—Dermatitis—Carmustine—lymphatic system cancer	0.000302	0.000796	CcSEcCtD
Pazopanib—Headache—Carmustine—lymphatic system cancer	0.0003	0.000792	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—lymphatic system cancer	0.000292	0.00077	CcSEcCtD
Pazopanib—Vomiting—Vincristine—lymphatic system cancer	0.000291	0.000767	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00029	0.000765	CcSEcCtD
Pazopanib—Rash—Vincristine—lymphatic system cancer	0.000289	0.000761	CcSEcCtD
Pazopanib—Dermatitis—Vincristine—lymphatic system cancer	0.000288	0.00076	CcSEcCtD
Pazopanib—Headache—Vincristine—lymphatic system cancer	0.000287	0.000756	CcSEcCtD
Pazopanib—Nausea—Carmustine—lymphatic system cancer	0.000285	0.000751	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—lymphatic system cancer	0.000284	0.000748	CcSEcCtD
Pazopanib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000283	0.000747	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000282	0.000743	CcSEcCtD
Pazopanib—Rash—Mitoxantrone—lymphatic system cancer	0.000281	0.000741	CcSEcCtD
Pazopanib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000281	0.00074	CcSEcCtD
Pazopanib—Chills—Methotrexate—lymphatic system cancer	0.000281	0.000739	CcSEcCtD
Pazopanib—Headache—Mitoxantrone—lymphatic system cancer	0.000279	0.000736	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—lymphatic system cancer	0.000276	0.000728	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—lymphatic system cancer	0.000274	0.000722	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—lymphatic system cancer	0.000272	0.000717	CcSEcCtD
Pazopanib—Erythema—Methotrexate—lymphatic system cancer	0.000272	0.000717	CcSEcCtD
Pazopanib—Nausea—Vincristine—lymphatic system cancer	0.000272	0.000717	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000267	0.000702	CcSEcCtD
Pazopanib—Nausea—Mitoxantrone—lymphatic system cancer	0.000265	0.000698	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—lymphatic system cancer	0.000256	0.000676	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—lymphatic system cancer	0.000252	0.000663	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—lymphatic system cancer	0.000244	0.000642	CcSEcCtD
Pazopanib—Cough—Methotrexate—lymphatic system cancer	0.000237	0.000626	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—lymphatic system cancer	0.000232	0.000611	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—lymphatic system cancer	0.000232	0.000611	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—lymphatic system cancer	0.000232	0.000611	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00023	0.000607	CcSEcCtD
Pazopanib—Infection—Methotrexate—lymphatic system cancer	0.000221	0.000582	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000218	0.000574	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000217	0.000573	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—lymphatic system cancer	0.000216	0.000569	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000215	0.000566	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—lymphatic system cancer	0.000212	0.000558	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000202	0.000533	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—lymphatic system cancer	0.000201	0.00053	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—lymphatic system cancer	0.000199	0.000526	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000198	0.000522	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—lymphatic system cancer	0.000197	0.00052	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000196	0.000515	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000193	0.000509	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000192	0.000505	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—lymphatic system cancer	0.000192	0.000505	CcSEcCtD
Pazopanib—Pain—Methotrexate—lymphatic system cancer	0.00019	0.000501	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000182	0.000479	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000176	0.000463	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—lymphatic system cancer	0.000159	0.00042	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—lymphatic system cancer	0.000157	0.000414	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000152	0.000401	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—lymphatic system cancer	0.000147	0.000387	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—lymphatic system cancer	0.000141	0.000372	CcSEcCtD
Pazopanib—Rash—Methotrexate—lymphatic system cancer	0.00014	0.000369	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—lymphatic system cancer	0.00014	0.000369	CcSEcCtD
Pazopanib—Headache—Methotrexate—lymphatic system cancer	0.000139	0.000367	CcSEcCtD
Pazopanib—Nausea—Methotrexate—lymphatic system cancer	0.000132	0.000348	CcSEcCtD
